Takahashi Mimasa, Dinse Gregg E, Foley Julie F, Hardisty Jerry F, Maronpot Robert R
Nippon Veterinary and Animal Science University, Tokyo, Japan.
Toxicol Pathol. 2002 Sep-Oct;30(5):599-605. doi: 10.1080/01926230290105776.
The overall and age-specific prevalences and multiplicities of spontaneous and chemically induced hepatocellular neoplasia were compared among male B6D2F1, B6C3F1, C3H (C3H/HeNCr1 MTV-), B6CF1, and C57BL/6 (C57BL/6NCr1) mice following a single intraperitoneal injection of 0.03 microM vinyl carbamate (VC)/g body weight or vehicle alone at 15 days of age. Additional groups of B6C3F1, C3H, and C57BL/6 males received 0.15 microM VC/g body weight at 15 days of age. For male B6D2F1, B6C3F1, C3H, B6CF1, and C57BL/6 mice, the estimated overall prevalences (and multiplicities) of hepatocellular adenomas or carcinomas in vehicle controls were 14.1% (0.19), 12.3% (0.15), 8.2% (0.10), 7.2% (0.09), and 2.4% (0.02), respectively. The analogous estimates in the low-dose group were 59.2% (1.19), 72.9% (4.07), 48.6% (1.99), 22.8% (0.29), and 43.9% (0.82). Analogous estimates for B6C3F1, C3H, and C57BL/6 mice in the high-dose group were 45.3% (4.29), 59.7% (6.63), and 46.8% (1.74), respectively. Age-specific multiplicity estimates suggested a progression from altered hepatocellular foci (AHF) to hepatocellular neoplasms. Further evidence of progression was provided by the temporal occurrence of hepatocellular adenomas before carcinomas, and the apparent origination of carcinomas within adenomas. Pulmonary metastases were observed in many of the mice with hepatocellular carcinomas. These findings confirm previous observations of strain differences in liver neoplasm response, suggest a progressive development from AHF to adenomas, and ultimately to carcinomas, and show sensitivity to VC-induced hepatocarcinogenesis in all 5 strains.
在15日龄时,给雄性B6D2F1、B6C3F1、C3H(C3H/HeNCr1 MTV-)、B6CF1和C57BL/6(C57BL/6NCr1)小鼠腹腔内单次注射0.03微摩尔/克体重的氨基甲酸乙烯酯(VC)或仅注射赋形剂,比较自发性和化学诱导性肝细胞肿瘤形成的总体患病率、年龄特异性患病率及瘤灶数。另外几组B6C3F1、C3H和C57BL/6雄性小鼠在15日龄时接受0.15微摩尔/克体重的VC注射。对于雄性B6D2F1、B6C3F1、C3H、B6CF1和C57BL/6小鼠,赋形剂对照组中肝细胞腺瘤或癌的估计总体患病率(及瘤灶数)分别为14.1%(0.19)、12.3%(0.15)、8.2%(0.10)、7.2%(0.09)和2.4%(0.02)。低剂量组的类似估计值分别为59.2%(1.19)、72.9%(4.07)、48.6%(1.99)、22.8%(0.29)和43.9%(0.82)。高剂量组中B6C3F1、C3H和C57BL/6小鼠的类似估计值分别为45.3%(4.29)、59.7%(6.63)和46.8%(1.74)。年龄特异性瘤灶数估计表明从肝细胞灶性改变(AHF)发展为肝细胞肿瘤。肝细胞腺瘤先于癌出现以及癌明显起源于腺瘤内,这为肿瘤进展提供了进一步证据。在许多患有肝细胞癌的小鼠中观察到肺转移。这些发现证实了先前关于肝脏肿瘤反应存在品系差异的观察结果,表明从AHF逐渐发展为腺瘤,最终发展为癌,并显示出所有5个品系对VC诱导的肝癌发生均敏感。